Coherus outlines $6M-$7M quarterly savings and lowers LOQTORZI cash-burn support target to $25M-$30M per quarter

• CEO Dennis Lanfear said the company is now pursuing “3 strategic alternatives designed to make Coherus a financially self-sustaining innovative oncology company with best-in-class and first-in-class products by the end of

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.